Gonadorelin
A GnRH analogue studied for testosterone and LH/FSH signaling.
Overview
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide that signals the pituitary to release LH and FSH, which in turn drive testosterone and estrogen production. It is used in research protocols aiming to support or "restart" the natural testosterone axis.
Dosing
Injection
- Starting dose
- 50 mcg
- Common dose
- 50–100 mcg
- Frequency
- 1–2× daily (bolus)
- Notes
- Pulsatile pumps dose ~5–20 mcg every 90 min; bolus research uses ~100 mcg.
Reported research/reference doses for educational purposes only. Always verify against primary literature and applicable regulations. Not medical advice.
How it works
Gonadorelin binds GnRH receptors on pituitary gonadotrophs, triggering the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In males, LH stimulates Leydig cells to produce testosterone. Pulsatile delivery mimics natural signaling, while continuous delivery paradoxically suppresses it.
Common research uses
- Testosterone axis support research
- LH and FSH stimulation studies
- Hypogonadism diagnostics (approved use)
- Pituitary function research
Considerations
Approved for diagnostic and specific therapeutic uses. Timing and delivery mode profoundly change its effect. Short half-life means frequent dosing. Prescription in most regions; research use elsewhere.